PDB 3lzf citation summary ‹ Protein Data Bank in Europe (PDBe)

Articles citing this publication (328)

Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. Wrammert J, Koutsonanos D, Li GM, Edupuganti S, Sui J, Morrissey M, McCausland M, Skountzou I, Hornig M, Lipkin WI, Mehta A, Razavi B, Del Rio C, Zheng NY, Lee JH, Huang M, Ali Z, Kaur K, Andrews S, Amara RR, Wang Y, Das SR, O'Donnell CD, Yewdell JW, Subbarao K, Marasco WA, Mulligan MJ, Compans R, Ahmed R, Wilson PC. J. Exp. Med. 208 181-193 (2011)
A highly conserved neutralizing epitope on group 2 influenza A viruses. Ekiert DC, Friesen RH, Bhabha G, Kwaks T, Jongeneelen M, Yu W, Ophorst C, Cox F, Korse HJ, Brandenburg B, Vogels R, Brakenhoff JP, Kompier R, Koldijk MH, Cornelissen LA, Poon LL, Peiris M, Koudstaal W, Wilson IA, Goudsmit J. Science 333 843-850 (2011)
Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Pancera M, Zhou T, Druz A, Georgiev IS, Soto C, Gorman J, Huang J, Acharya P, Chuang GY, Ofek G, Stewart-Jones GB, Stuckey J, Bailer RT, Joyce MG, Louder MK, Tumba N, Yang Y, Zhang B, Cohen MS, Haynes BF, Mascola JR, Morris L, Munro JB, Blanchard SC, Mothes W, Connors M, Kwong PD. Nature 514 455-461 (2014)
Highly conserved protective epitopes on influenza B viruses. Dreyfus C, Laursen NS, Kwaks T, Zuijdgeest D, Khayat R, Ekiert DC, Lee JH, Metlagel Z, Bujny MV, Jongeneelen M, van der Vlugt R, Lamrani M, Korse HJ, Geelen E, Sahin Ö, Sieuwerts M, Brakenhoff JP, Vogels R, Li OT, Poon LL, Peiris M, Koudstaal W, Ward AB, Wilson IA, Goudsmit J, Friesen RH. Science 337 1343-1348 (2012)
Cross-neutralization of influenza A viruses mediated by a single antibody loop. Ekiert DC, Kashyap AK, Steel J, Rubrum A, Bhabha G, Khayat R, Lee JH, Dillon MA, O'Neil RE, Faynboym AM, Horowitz M, Horowitz L, Ward AB, Palese P, Webby R, Lerner RA, Bhatt RR, Wilson IA. Nature 489 526-532 (2012)
Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. Skowronski DM, Janjua NZ, De Serres G, Sabaiduc S, Eshaghi A, Dickinson JA, Fonseca K, Winter AL, Gubbay JB, Krajden M, Petric M, Charest H, Bastien N, Kwindt TL, Mahmud SM, Van Caeseele P, Li Y. PLoS ONE 9 e92153 (2014)
Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies. Sasaki S, Sullivan M, Narvaez CF, Holmes TH, Furman D, Zheng NY, Nishtala M, Wrammert J, Smith K, James JA, Dekker CL, Davis MM, Wilson PC, Greenberg HB, He XS. J. Clin. Invest. 121 3109-3119 (2011)
Cross-reactive CD8+ T-cell immunity between the pandemic H1N1-2009 and H1N1-1918 influenza A viruses. Gras S, Kedzierski L, Valkenburg SA, Laurie K, Liu YC, Denholm JT, Richards MJ, Rimmelzwaan GF, Kelso A, Doherty PC, Turner SJ, Rossjohn J, Kedzierska K. Proc. Natl. Acad. Sci. U.S.A. 107 12599-12604 (2010)
A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin. Krause JC, Tsibane T, Tumpey TM, Huffman CJ, Basler CF, Crowe JE. J. Virol. 85 10905-10908 (2011)
The 2009 pandemic H1N1 neuraminidase N1 lacks the 150-cavity in its active site. Li Q, Qi J, Zhang W, Vavricka CJ, Shi Y, Wei J, Feng E, Shen J, Chen J, Liu D, He J, Yan J, Liu H, Jiang H, Teng M, Li X, Gao GF. Nat. Struct. Mol. Biol. 17 1266-1268 (2010)
A pan-H1 anti-hemagglutinin monoclonal antibody with potent broad-spectrum efficacy in vivo. Tan GS, Krammer F, Eggink D, Kongchanagul A, Moran TM, Palese P. J. Virol. 86 6179-6188 (2012)
Potential antigenic explanation for atypical H1N1 infections among middle-aged adults during the 2013-2014 influenza season. Linderman SL, Chambers BS, Zost SJ, Parkhouse K, Li Y, Herrmann C, Ellebedy AH, Carter DM, Andrews SF, Zheng NY, Huang M, Huang Y, Strauss D, Shaz BH, Hodinka RL, Reyes-Terán G, Ross TM, Wilson PC, Ahmed R, Bloom JD, Hensley SE. Proc. Natl. Acad. Sci. U.S.A. 111 15798-15803 (2014)
Immune history shapes specificity of pandemic H1N1 influenza antibody responses. Li Y, Myers JL, Bostick DL, Sullivan CB, Madara J, Linderman SL, Liu Q, Carter DM, Wrammert J, Esposito S, Principi N, Plotkin JB, Ross TM, Ahmed R, Wilson PC, Hensley SE. J. Exp. Med. 210 1493-1500 (2013)
Structural characterization of the hemagglutinin receptor specificity from the 2009 H1N1 influenza pandemic. Xu R, McBride R, Nycholat CM, Paulson JC, Wilson IA. J. Virol. 86 982-990 (2012)
Functional balance of the hemagglutinin and neuraminidase activities accompanies the emergence of the 2009 H1N1 influenza pandemic. Xu R, Zhu X, McBride R, Nycholat CM, Yu W, Paulson JC, Wilson IA. J. Virol. 86 9221-9232 (2012)
A recurring motif for antibody recognition of the receptor-binding site of influenza hemagglutinin. Xu R, Krause JC, McBride R, Paulson JC, Crowe JE, Wilson IA. Nat. Struct. Mol. Biol. 20 363-370 (2013)
Heterosubtypic antibody recognition of the influenza virus hemagglutinin receptor binding site enhanced by avidity. Lee PS, Yoshida R, Ekiert DC, Sakai N, Suzuki Y, Takada A, Wilson IA. Proc. Natl. Acad. Sci. U.S.A. 109 17040-17045 (2012)
Pandemic H1N1 Influenza Infection and Vaccination in Humans Induces Cross-Protective Antibodies that Target the Hemagglutinin Stem. Thomson CA, Wang Y, Jackson LM, Olson M, Wang W, Liavonchanka A, Keleta L, Silva V, Diederich S, Jones RB, Gubbay J, Pasick J, Petric M, Jean F, Allen VG, Brown EG, Rini JM, Schrader JW. Front Immunol 3 87 (2012)
Variations in the hemagglutinin of the 2009 H1N1 pandemic virus: potential for strains with altered virulence phenotype? Ye J, Sorrell EM, Cai Y, Shao H, Xu K, Pena L, Hickman D, Song H, Angel M, Medina RA, Manicassamy B, Garcia-Sastre A, Perez DR. PLoS Pathog. 6 e1001145 (2010)
A single amino acid in the stalk region of the H1N1pdm influenza virus HA protein affects viral fusion, stability and infectivity. Cotter CR, Jin H, Chen Z. PLoS Pathog. 10 e1003831 (2014)
Crystal structure of the swine-origin A (H1N1)-2009 influenza A virus hemagglutinin (HA) reveals similar antigenicity to that of the 1918 pandemic virus. Zhang W, Qi J, Shi Y, Li Q, Gao F, Sun Y, Lu X, Lu Q, Vavricka CJ, Liu D, Yan J, Gao GF. Protein Cell 1 459-467 (2010)
Sensitivity and specificity of serologic assays for detection of human infection with 2009 pandemic H1N1 virus in U.S. populations. Veguilla V, Hancock K, Schiffer J, Gargiullo P, Lu X, Aranio D, Branch A, Dong L, Holiday C, Liu F, Steward-Clark E, Sun H, Tsang B, Wang D, Whaley M, Bai Y, Cronin L, Browning P, Dababneh H, Noland H, Thomas L, Foster L, Quinn CP, Soroka SD, Katz JM. J. Clin. Microbiol. 49 2210-2215 (2011)
Flow cytometry reveals that H5N1 vaccination elicits cross-reactive stem-directed antibodies from multiple Ig heavy-chain lineages. Whittle JR, Wheatley AK, Wu L, Lingwood D, Kanekiyo M, Ma SS, Narpala SR, Yassine HM, Frank GM, Yewdell JW, Ledgerwood JE, Wei CJ, McDermott AB, Graham BS, Koup RA, Nabel GJ. J. Virol. 88 4047-4057 (2014)
Structural characterization of an early fusion intermediate of influenza virus hemagglutinin. Xu R, Wilson IA. J. Virol. 85 5172-5182 (2011)
Seasonal FluMist vaccination induces cross-reactive T cell immunity against H1N1 (2009) influenza and secondary bacterial infections. Sun K, Ye J, Perez DR, Metzger DW. J Immunol 186 987-993 (2011)
Acid stability of the hemagglutinin protein regulates H5N1 influenza virus pathogenicity. DuBois RM, Zaraket H, Reddivari M, Heath RJ, White SW, Russell CJ. PLoS Pathog. 7 e1002398 (2011)
Antibody recognition of the pandemic H1N1 Influenza virus hemagglutinin receptor binding site. Hong M, Lee PS, Hoffman RM, Zhu X, Krause JC, Laursen NS, Yoon SI, Song L, Tussey L, Crowe JE, Ward AB, Wilson IA. J. Virol. 87 12471-12480 (2013)
Quantifying influenza virus diversity and transmission in humans. Poon LL, Song T, Rosenfeld R, Lin X, Rogers MB, Zhou B, Sebra R, Halpin RA, Guan Y, Twaddle A, DePasse JV, Stockwell TB, Wentworth DE, Holmes EC, Greenbaum B, Peiris JS, Cowling BJ, Ghedin E. Nat. Genet. 48 195-200 (2016)
Epitope-specific human influenza antibody repertoires diversify by B cell intraclonal sequence divergence and interclonal convergence. Krause JC, Tsibane T, Tumpey TM, Huffman CJ, Briney BS, Smith SA, Basler CF, Crowe JE. J. Immunol. 187 3704-3711 (2011)
Receptor mimicry by antibody F045-092 facilitates universal binding to the H3 subtype of influenza virus. Lee PS, Ohshima N, Stanfield RL, Yu W, Iba Y, Okuno Y, Kurosawa Y, Wilson IA. Nat Commun 5 3614 (2014)
Novel reassortment of Eurasian avian-like and pandemic/2009 influenza viruses in swine: infectious potential for humans. Zhu H, Zhou B, Fan X, Lam TT, Wang J, Chen A, Chen X, Chen H, Webster RG, Webby R, Peiris JS, Smith DK, Guan Y. J. Virol. 85 10432-10439 (2011)
Structure and accessibility of HA trimers on intact 2009 H1N1 pandemic influenza virus to stem region-specific neutralizing antibodies. Harris AK, Meyerson JR, Matsuoka Y, Kuybeda O, Moran A, Bliss D, Das SR, Yewdell JW, Sapiro G, Subbarao K, Subramaniam S. Proc. Natl. Acad. Sci. U.S.A. 110 4592-4597 (2013)
Cross-reactive neutralizing antibodies directed against pandemic H1N1 2009 virus are protective in a highly sensitive DBA/2 mouse influenza model. Boon AC, deBeauchamp J, Krauss S, Rubrum A, Webb AD, Webster RG, McElhaney J, Webby RJ. J. Virol. 84 7662-7667 (2010)
Mutations in PA, NP, and HA of a pandemic (H1N1) 2009 influenza virus contribute to its adaptation to mice. Sakabe S, Ozawa M, Takano R, Iwastuki-Horimoto K, Kawaoka Y. Virus Res. 158 124-129 (2011)
Comparison of the receptor binding properties of contemporary swine isolates and early human pandemic H1N1 isolates (Novel 2009 H1N1). Bradley KC, Jones CA, Tompkins SM, Tripp RA, Russell RJ, Gramer MR, Heimburg-Molinaro J, Smith DF, Cummings RD, Steinhauer DA. Virology 413 169-182 (2011)
Bacterial HA1 vaccine against pandemic H5N1 influenza virus: evidence of oligomerization, hemagglutination, and cross-protective immunity in ferrets. Khurana S, Verma S, Verma N, Crevar CJ, Carter DM, Manischewitz J, King LR, Ross TM, Golding H. J. Virol. 85 1246-1256 (2011)
Seasonal influenza vaccine and protection against pandemic (H1N1) 2009-associated illness among US military personnel. Johns MC, Eick AA, Blazes DL, Lee SE, Perdue CL, Lipnick R, Vest KG, Russell KL, DeFraites RF, Sanchez JL. PLoS ONE 5 e10722 (2010)
A human antibody recognizing a conserved epitope of H5 hemagglutinin broadly neutralizes highly pathogenic avian influenza H5N1 viruses. Hu H, Voss J, Zhang G, Buchy P, Zuo T, Wang L, Wang F, Zhou F, Wang G, Tsai C, Calder L, Gamblin SJ, Zhang L, Deubel V, Zhou B, Skehel JJ, Zhou P. J. Virol. 86 2978-2989 (2012)
Design of Escherichia coli-expressed stalk domain immunogens of H1N1 hemagglutinin that protect mice from lethal challenge. Bommakanti G, Lu X, Citron MP, Najar TA, Heidecker GJ, ter Meulen J, Varadarajan R, Liang X. J. Virol. 86 13434-13444 (2012)
Receptor specificity of subtype H1 influenza A viruses isolated from swine and humans in the United States. Chen LM, Rivailler P, Hossain J, Carney P, Balish A, Perry I, Davis CT, Garten R, Shu B, Xu X, Klimov A, Paulson JC, Cox NJ, Swenson S, Stevens J, Vincent A, Gramer M, Donis RO. Virology 412 401-410 (2011)
Immune response following H1N1pdm09 vaccination: differences in antibody repertoire and avidity in young adults and elderly populations stratified by age and gender. Khurana S, Verma N, Talaat KR, Karron RA, Golding H. J. Infect. Dis. 205 610-620 (2012)
Influenza human monoclonal antibody 1F1 interacts with three major antigenic sites and residues mediating human receptor specificity in H1N1 viruses. Tsibane T, Ekiert DC, Krause JC, Martinez O, Crowe JE, Wilson IA, Basler CF. PLoS Pathog. 8 e1003067 (2012)
Comparing pandemic to seasonal influenza mortality: moderate impact overall but high mortality in young children. Wijngaard CC, Asten Lv, Koopmans MP, Pelt Wv, Nagelkerke NJ, Wielders CC, Lier Av, Hoek Wv, Meijer A, Donker GA, Dijkstra F, Harmsen C, Sande MA, Kretzschmar M. PLoS ONE 7 e31197 (2012)
Focused antibody response to influenza linked to antigenic drift. Huang KY, Rijal P, Schimanski L, Powell TJ, Lin TY, McCauley JW, Daniels RS, Townsend AR. J. Clin. Invest. 125 2631-2645 (2015)
Pulmonary infection with influenza A virus induces site-specific germinal center and T follicular helper cell responses. Boyden AW, Legge KL, Waldschmidt TJ. PLoS ONE 7 e40733 (2012)
Synergistic adaptive mutations in the hemagglutinin and polymerase acidic protein lead to increased virulence of pandemic 2009 H1N1 influenza A virus in mice. Seyer R, Hrincius ER, Ritzel D, Abt M, Mellmann A, Marjuki H, Kühn J, Wolff T, Ludwig S, Ehrhardt C. J. Infect. Dis. 205 262-271 (2012)
Immunodominance of antigenic site B over site A of hemagglutinin of recent H3N2 influenza viruses. Popova L, Smith K, West AH, Wilson PC, James JA, Thompson LF, Air GM. PLoS ONE 7 e41895 (2012)
Vaccinate for the next H2N2 pandemic now. Nabel GJ, Wei CJ, Ledgerwood JE. Nature 471 157-158 (2011)
Age-associated cross-reactive antibody-dependent cellular cytotoxicity toward 2009 pandemic influenza A virus subtype H1N1. Jegaskanda S, Laurie KL, Amarasena TH, Winnall WR, Kramski M, De Rose R, Barr IG, Brooks AG, Reading PC, Kent SJ. J. Infect. Dis. 208 1051-1061 (2013)
A new common mutation in the hemagglutinin of the 2009 (H1N1) influenza A virus. Maurer-Stroh S, Lee RT, Eisenhaber F, Cui L, Phuah SP, Lin RT. PLoS Curr 2 RRN1162 (2010)
A single base-pair change in 2009 H1N1 hemagglutinin increases human receptor affinity and leads to efficient airborne viral transmission in ferrets. Jayaraman A, Pappas C, Raman R, Belser JA, Viswanathan K, Shriver Z, Tumpey TM, Sasisekharan R. PLoS ONE 6 e17616 (2011)
B cell response and hemagglutinin stalk-reactive antibody production in different age cohorts following 2009 H1N1 influenza virus vaccination. Sangster MY, Baer J, Santiago FW, Fitzgerald T, Ilyushina NA, Sundararajan A, Henn AD, Krammer F, Yang H, Luke CJ, Zand MS, Wright PF, Treanor JJ, Topham DJ, Subbarao K. Clin. Vaccine Immunol. 20 867-876 (2013)
Glycan shielding of the influenza virus hemagglutinin contributes to immunopathology in mice. Wanzeck K, Boyd KL, McCullers JA. Am. J. Respir. Crit. Care Med. 183 767-773 (2011)
Only two residues are responsible for the dramatic difference in receptor binding between swine and new pandemic H1 hemagglutinin. de Vries RP, de Vries E, Moore KS, Rigter A, Rottier PJ, de Haan CA. J. Biol. Chem. 286 5868-5875 (2011)
Predictors of clinical outcome in a national hospitalised cohort across both waves of the influenza A/H1N1 pandemic 2009-2010 in the UK. Myles PR, Semple MG, Lim WS, Openshaw PJ, Gadd EM, Read RC, Taylor BL, Brett SJ, McMenamin J, Enstone JE, Armstrong C, Bannister B, Nicholson KG, Nguyen-Van-Tam JS, Influenza Clinical Information Network (FLU-CIN). Thorax 67 709-717 (2012)
High performance screening, structural and molecular dynamics analysis to identify H1 inhibitors from TCM Database@Taiwan. Chang SS, Huang HJ, Chen CY. Mol Biosyst 7 3366-3374 (2011)
Molecular basis of the receptor binding specificity switch of the hemagglutinins from both the 1918 and 2009 pandemic influenza A viruses by a D225G substitution. Zhang W, Shi Y, Qi J, Gao F, Li Q, Fan Z, Yan J, Gao GF. J. Virol. 87 5949-5958 (2013)
The receptor-binding domain of influenza virus hemagglutinin produced in Escherichia coli folds into its native, immunogenic structure. DuBois RM, Aguilar-Yañez JM, Mendoza-Ochoa GI, Oropeza-Almazán Y, Schultz-Cherry S, Alvarez MM, White SW, Russell CJ. J. Virol. 85 865-872 (2011)
The Mutational Robustness of Influenza A Virus. Visher E, Whitefield SE, McCrone JT, Fitzsimmons W, Lauring AS. PLoS Pathog. 12 e1005856 (2016)
Impact of prior seasonal influenza vaccination and infection on pandemic A (H1N1) influenza virus replication in ferrets. Ellebedy AH, Ducatez MF, Duan S, Stigger-Rosser E, Rubrum AM, Govorkova EA, Webster RG, Webby RJ. Vaccine 29 3335-3339 (2011)
Pandemic 2009 H1N1 vaccine protects against 1918 Spanish influenza virus. Medina RA, Manicassamy B, Stertz S, Seibert CW, Hai R, Belshe RB, Frey SE, Basler CF, Palese P, García-Sastre A. Nat Commun 1 28 (2010)
Glycosylations in the globular head of the hemagglutinin protein modulate the virulence and antigenic properties of the H1N1 influenza viruses. Medina RA, Stertz S, Manicassamy B, Zimmermann P, Sun X, Albrecht RA, Uusi-Kerttula H, Zagordi O, Belshe RB, Frey SE, Tumpey TM, García-Sastre A. Sci Transl Med 5 187ra70 (2013)
Immunogenicity, boostability, and sustainability of the immune response after vaccination against Influenza A virus (H1N1) 2009 in a healthy population. Huijskens E, Rossen J, Mulder P, van Beek R, van Vugt H, Verbakel J, Rimmelzwaan G, Koopmans M, Peeters M. Clin. Vaccine Immunol. 18 1401-1405 (2011)
Increased viral loads and exacerbated innate host responses in aged macaques infected with the 2009 pandemic H1N1 influenza A virus. Josset L, Engelmann F, Haberthur K, Kelly S, Park B, Kawoaka Y, García-Sastre A, Katze MG, Messaoudi I. J. Virol. 86 11115-11127 (2012)
Novel H7N9 influenza virus shows low infectious dose, high growth rate, and efficient contact transmission in the guinea pig model. Gabbard JD, Dlugolenski D, Van Riel D, Marshall N, Galloway SE, Howerth EW, Campbell PJ, Jones C, Johnson S, Byrd-Leotis L, Steinhauer DA, Kuiken T, Tompkins SM, Tripp R, Lowen AC, Steel J. J. Virol. 88 1502-1512 (2014)
Two Escape Mechanisms of Influenza A Virus to a Broadly Neutralizing Stalk-Binding Antibody. Chai N, Swem LR, Reichelt M, Chen-Harris H, Luis E, Park S, Fouts A, Lupardus P, Wu TD, Li O, McBride J, Lawrence M, Xu M, Tan MW. PLoS Pathog. 12 e1005702 (2016)
Influenza virus H1N1pdm09 infections in the young and old: evidence of greater antibody diversity and affinity for the hemagglutinin globular head domain (HA1 Domain) in the elderly than in young adults and children. Verma N, Dimitrova M, Carter DM, Crevar CJ, Ross TM, Golding H, Khurana S. J. Virol. 86 5515-5522 (2012)
Mutation analysis of 2009 pandemic influenza A(H1N1) viruses collected in Japan during the peak phase of the pandemic. Morlighem JÉ, Aoki S, Kishima M, Hanami M, Ogawa C, Jalloh A, Takahashi Y, Kawai Y, Saga S, Hayashi E, Ban T, Izumi S, Wada A, Mano M, Fukunaga M, Kijima Y, Shiomi M, Inoue K, Hata T, Koretsune Y, Kudo K, Himeno Y, Hirai A, Takahashi K, Sakai-Tagawa Y, Iwatsuki-Horimoto K, Kawaoka Y, Hayashizaki Y, Ishikawa T. PLoS ONE 6 e18956 (2011)
Sequential seasonal H1N1 influenza virus infections protect ferrets against novel 2009 H1N1 influenza virus. Carter DM, Bloom CE, Nascimento EJ, Marques ET, Craigo JK, Cherry JL, Lipman DJ, Ross TM. J. Virol. 87 1400-1410 (2013)
Genetic requirement for hemagglutinin glycosylation and its implications for influenza A H1N1 virus evolution. Kim JI, Lee I, Park S, Hwang MW, Bae JY, Lee S, Heo J, Park MS, García-Sastre A, Park MS. J. Virol. 87 7539-7549 (2013)
Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits. Robinson JE, Hastie KM, Cross RW, Yenni RE, Elliott DH, Rouelle JA, Kannadka CB, Smira AA, Garry CE, Bradley BT, Yu H, Shaffer JG, Boisen ML, Hartnett JN, Zandonatti MA, Rowland MM, Heinrich ML, Martínez-Sobrido L, Cheng B, de la Torre JC, Andersen KG, Goba A, Momoh M, Fullah M, Gbakie M, Kanneh L, Koroma VJ, Fonnie R, Jalloh SC, Kargbo B, Vandi MA, Gbetuwa M, Ikponmwosa O, Asogun DA, Okokhere PO, Follarin OA, Schieffelin JS, Pitts KR, Geisbert JB, Kulakoski PC, Wilson RB, Happi CT, Sabeti PC, Gevao SM, Khan SH, Grant DS, Geisbert TW, Saphire EO, Branco LM, Garry RF. Nat Commun 7 11544 (2016)
Prevalence of seropositivity to pandemic influenza A/H1N1 virus in the United States following the 2009 pandemic. Reed C, Katz JM, Hancock K, Balish A, Fry AM, H1N1 Serosurvey Working Group. PLoS ONE 7 e48187 (2012)
Recombinant antibodies encoded by IGHV1-69 react with pUL32, a phosphoprotein of cytomegalovirus and B-cell superantigen. Steininger C, Widhopf GF, Ghia EM, Morello CS, Vanura K, Sanders R, Spector D, Guiney D, Jäger U, Kipps TJ. Blood 119 2293-2301 (2012)
Conserved neutralizing epitope at globular head of hemagglutinin in H3N2 influenza viruses. Iba Y, Fujii Y, Ohshima N, Sumida T, Kubota-Koketsu R, Ikeda M, Wakiyama M, Shirouzu M, Okada J, Okuno Y, Kurosawa Y, Yokoyama S. J. Virol. 88 7130-7144 (2014)
Cross-neutralizing antibodies to pandemic 2009 H1N1 and recent seasonal H1N1 influenza A strains influenced by a mutation in hemagglutinin subunit 2. Wang W, Anderson CM, De Feo CJ, Zhuang M, Yang H, Vassell R, Xie H, Ye Z, Scott D, Weiss CD. PLoS Pathog. 7 e1002081 (2011)
Humoral and cell-mediated immunity to pandemic H1N1 influenza in a Canadian cohort one year post-pandemic: implications for vaccination. Wagar LE, Rosella L, Crowcroft N, Lowcock B, Drohomyrecky PC, Foisy J, Gubbay J, Rebbapragada A, Winter AL, Achonu C, Ward BJ, Watts TH. PLoS ONE 6 e28063 (2011)
A unique and conserved neutralization epitope in H5N1 influenza viruses identified by an antibody against the A/Goose/Guangdong/1/96 hemagglutinin. Zhu X, Guo YH, Jiang T, Wang YD, Chan KH, Li XF, Yu W, McBride R, Paulson JC, Yuen KY, Qin CF, Che XY, Wilson IA. J. Virol. 87 12619-12635 (2013)
An influenza A/H1N1/2009 hemagglutinin vaccine produced in Escherichia coli. Aguilar-Yáñez JM, Portillo-Lara R, Mendoza-Ochoa GI, García-Echauri SA, López-Pacheco F, Bulnes-Abundis D, Salgado-Gallegos J, Lara-Mayorga IM, Webb-Vargas Y, León-Angel FO, Rivero-Aranda RE, Oropeza-Almazán Y, Ruiz-Palacios GM, Zertuche-Guerra MI, DuBois RM, White SW, Schultz-Cherry S, Russell CJ, Alvarez MM. PLoS ONE 5 e11694 (2010)
Comparative characterization of the glycosylation profiles of an influenza hemagglutinin produced in plant and insect hosts. Zhang S, Sherwood RW, Yang Y, Fish T, Chen W, McCardle JA, Jones RM, Yusibov V, May ER, Rose JK, Thannhauser TW. Proteomics 12 1269-1288 (2012)
Improving pandemic influenza risk assessment. Russell CA, Kasson PM, Donis RO, Riley S, Dunbar J, Rambaut A, Asher J, Burke S, Davis CT, Garten RJ, Gnanakaran S, Hay SI, Herfst S, Lewis NS, Lloyd-Smith JO, Macken CA, Maurer-Stroh S, Neuhaus E, Parrish CR, Pepin KM, Shepard SS, Smith DL, Suarez DL, Trock SC, Widdowson MA, George DB, Lipsitch M, Bloom JD. Elife 3 e03883 (2014)
Subtype- and antigenic site-specific differences in biophysical influences on evolution of influenza virus hemagglutinin. Stray SJ, Pittman LB. Virol. J. 9 91 (2012)
Using sequence data to infer the antigenicity of influenza virus. Sun H, Yang J, Zhang T, Long LP, Jia K, Yang G, Webby RJ, Wan XF. MBio 4 (2013)
Identification of amino acid substitutions supporting antigenic change of influenza A(H1N1)pdm09 viruses. Koel BF, Mögling R, Chutinimitkul S, Fraaij PL, Burke DF, van der Vliet S, de Wit E, Bestebroer TM, Rimmelzwaan GF, Osterhaus AD, Smith DJ, Fouchier RA, de Graaf M. J. Virol. 89 3763-3775 (2015)
Networks link antigenic and receptor-binding sites of influenza hemagglutinin: mechanistic insight into fitter strain propagation. Soundararajan V, Zheng S, Patel N, Warnock K, Raman R, Wilson IA, Raguram S, Sasisekharan V, Sasisekharan R. Sci Rep 1 200 (2011)
Prevalence of antibodies to 2009 pandemic influenza A (H1N1) virus in German adult population in pre- and post-pandemic period. Dudareva S, Schweiger B, Thamm M, Höhle M, Stark K, Krause G, Buda S, Haas W. PLoS ONE 6 e21340 (2011)
Structure of a PE-PPE-EspG complex from Mycobacterium tuberculosis reveals molecular specificity of ESX protein secretion. Ekiert DC, Cox JS. Proc. Natl. Acad. Sci. U.S.A. 111 14758-14763 (2014)
Evolutionary pathways of the pandemic influenza A (H1N1) 2009 in the UK. Galiano M, Agapow PM, Thompson C, Platt S, Underwood A, Ellis J, Myers R, Green J, Zambon M. PLoS ONE 6 e23779 (2011)
Genetic characterization of human influenza viruses in the pandemic (2009-2010) and post-pandemic (2010-2011) periods in Japan. Dapat IC, Dapat C, Baranovich T, Suzuki Y, Kondo H, Shobugawa Y, Saito R, Suzuki H, Japanese Influenza Collaborative Study Group. PLoS ONE 7 e36455 (2012)
Antigenic stability of H1N1 pandemic vaccines correlates with vaccine strain. Farnsworth A, Cyr TD, Li C, Wang J, Li X. Vaccine 29 1529-1533 (2011)
Effect of priming with H1N1 influenza viruses of variable antigenic distances on challenge with 2009 pandemic H1N1 virus. O'Donnell CD, Wright A, Vogel LN, Wei CJ, Nabel GJ, Subbarao K. J. Virol. 86 8625-8633 (2012)
OptMAVEn--a new framework for the de novo design of antibody variable region models targeting specific antigen epitopes. Li T, Pantazes RJ, Maranas CD. PLoS ONE 9 e105954 (2014)
Comprehensive analysis of antibody recognition in convalescent humans from highly pathogenic avian influenza H5N1 infection. Zuo T, Sun J, Wang G, Jiang L, Zuo Y, Li D, Shi X, Liu X, Fan S, Ren H, Hu H, Sun L, Zhou B, Liang M, Zhou P, Wang X, Zhang L. Nat Commun 6 8855 (2015)
Selection of antigenically advanced variants of seasonal influenza viruses. Li C, Hatta M, Burke DF, Ping J, Zhang Y, Ozawa M, Taft AS, Das SC, Hanson AP, Song J, Imai M, Wilker PR, Watanabe T, Watanabe S, Ito M, Iwatsuki-Horimoto K, Russell CA, James SL, Skepner E, Maher EA, Neumann G, Klimov AI, Kelso A, McCauley J, Wang D, Shu Y, Odagiri T, Tashiro M, Xu X, Wentworth DE, Katz JM, Cox NJ, Smith DJ, Kawaoka Y. Nat Microbiol 1 16058 (2016)
A mutation in the receptor binding site enhances infectivity of 2009 H1N1 influenza hemagglutinin pseudotypes without changing antigenicity. Wang W, Castelán-Vega JA, Jiménez-Alberto A, Vassell R, Ye Z, Weiss CD. Virology 407 374-380 (2010)
All that glitters is not gold--founder effects complicate associations of flu mutations to disease severity. Lee RT, Santos CL, de Paiva TM, Cui L, Sirota FL, Eisenhaber F, Maurer-Stroh S. Virol. J. 7 297 (2010)
Conserved epitope on influenza-virus hemagglutinin head defined by a vaccine-induced antibody. Raymond DD, Bajic G, Ferdman J, Suphaphiphat P, Settembre EC, Moody MA, Schmidt AG, Harrison SC. Proc. Natl. Acad. Sci. U.S.A. 115 168-173 (2018)
Cross-reactive neutralizing antibody against pandemic 2009 H1N1 influenza a virus in intravenous immunoglobulin preparations. Hong DK, Tremoulet AH, Burns JC, Lewis DB. Pediatr. Infect. Dis. J. 30 67-69 (2011)
HLA targeting efficiency correlates with human T-cell response magnitude and with mortality from influenza A infection. Hertz T, Oshansky CM, Roddam PL, DeVincenzo JP, Caniza MA, Jojic N, Mallal S, Phillips E, James I, Halloran ME, Thomas PG, Corey L. Proc. Natl. Acad. Sci. U.S.A. 110 13492-13497 (2013)
Identifying antigenicity-associated sites in highly pathogenic H5N1 influenza virus hemagglutinin by using sparse learning. Cai Z, Ducatez MF, Yang J, Zhang T, Long LP, Boon AC, Webby RJ, Wan XF. J. Mol. Biol. 422 145-155 (2012)
Characterization of influenza vaccine immunogenicity using influenza antigen microarrays. Price JV, Jarrell JA, Furman D, Kattah NH, Newell E, Dekker CL, Davis MM, Utz PJ. PLoS ONE 8 e64555 (2013)
Free-energy simulations reveal that both hydrophobic and polar interactions are important for influenza hemagglutinin antibody binding. Xia Z, Huynh T, Kang SG, Zhou R. Biophys. J. 102 1453-1461 (2012)
Searching for sharp drops in the incidence of pandemic A/H1N1 influenza by single year of age. Jacobs JH, Archer BN, Baker MG, Cowling BJ, Heffernan RT, Mercer G, Uez O, Hanshaoworakul W, Viboud C, Schwartz J, Tchetgen Tchetgen E, Lipsitch M. PLoS ONE 7 e42328 (2012)
Age-Related Pathology Associated with H1N1 A/California/07/2009 Influenza Virus Infection. Bissel SJ, Carter CE, Wang G, Johnson SK, Lashua LP, Kelvin AA, Wiley CA, Ghedin E, Ross TM. Am J Pathol 189 2389-2399 (2019)
Antigenically intact hemagglutinin in circulating avian and swine influenza viruses and potential for H3N2 pandemic. Tharakaraman K, Raman R, Stebbins NW, Viswanathan K, Sasisekharan V, Sasisekharan R. Sci Rep 3 1822 (2013)
First exposure to the pandemic H1N1 virus induced broadly neutralizing antibodies targeting hemagglutinin head epitopes. Guthmiller JJ, Han J, Li L, Freyn AW, Liu STH, Stovicek O, Stamper CT, Dugan HL, Tepora ME, Utset HA, Bitar DJ, Hamel NJ, Changrob S, Zheng NY, Huang M, Krammer F, Nachbagauer R, Palese P, Ward AB, Wilson PC. Sci Transl Med 13 eabg4535 (2021)
Antigenicity of the 2015-2016 seasonal H1N1 human influenza virus HA and NA proteins. Clark AM, DeDiego ML, Anderson CS, Wang J, Yang H, Nogales A, Martinez-Sobrido L, Zand MS, Sangster MY, Topham DJ. PLoS ONE 12 e0188267 (2017)
Comparison of neutralizing antibody and cell-mediated immune responses to pandemic H1N1 2009 influenza virus before and after H1N1 2009 influenza vaccination of elderly subjects and healthcare workers. Hsu JP, Phoon MC, Koh GC, Chen MI, Lee VJ, Wu Y, Xie ML, Cheong A, Leo YS, Chow VT. Int. J. Infect. Dis. 16 e621-7 (2012)
Emergent 2009 influenza A(H1N1) viruses containing HA D222N mutation associated with severe clinical outcomes in the Americas. Houng HS, Garner J, Zhou Y, Lyons A, Kuschner R, Deye G, St Clair K, Douce RW, Chicaiza W, Blair PJ, Myers CA, Burke RL, Sanchez JL, Williams M, Halsey ES. J. Clin. Virol. 53 12-15 (2012)
Molecular characterization of the predominant influenza A(H1N1)pdm09 virus in Mexico, December 2011-February 2012. de la Rosa-Zamboni D, Vázquez-Pérez JA, Avila-Ríos S, Carranco-Arenas AP, Ormsby CE, Cummings CA, Soto-Nava M, Hernández-Hernández VA, Orozco-Sánchez CO, la Barrera CA, Pérez-Padilla R, Reyes-Terán G. PLoS ONE 7 e50116 (2012)
Natural and directed antigenic drift of the H1 influenza virus hemagglutinin stalk domain. Anderson CS, Ortega S, Chaves FA, Clark AM, Yang H, Topham DJ, DeDiego ML. Sci Rep 7 14614 (2017)
One-step detection of the 2009 pandemic influenza A(H1N1) virus by the RT-SmartAmp assay and its clinical validation. Kawai Y, Kimura Y, Lezhava A, Kanamori H, Usui K, Hanami T, Soma T, Morlighem JÉ, Saga S, Ishizu Y, Aoki S, Endo R, Oguchi-Katayama A, Kogo Y, Mitani Y, Ishidao T, Kawakami C, Kurata H, Furuya Y, Saito T, Okazaki N, Chikahira M, Hayashi E, Tsuruoka S, Toguchi T, Saito Y, Ban T, Izumi S, Uryu H, Kudo K, Sakai-Tagawa Y, Kawaoka Y, Hirai A, Hayashizaki Y, Ishikawa T. PLoS ONE 7 e30236 (2012)
Antibodies against conserved antigens provide opportunities for reform in influenza vaccine design. Kaminski DA, Lee FE. Front Immunol 2 76 (2011)
Enrichment of variations in KIR3DL1/S1 and KIR2DL2/L3 among H1N1/09 ICU patients: an exploratory study. La D, Czarnecki C, El-Gabalawy H, Kumar A, Meyers AF, Bastien N, Simonsen JN, Plummer FA, Luo M. PLoS ONE 6 e29200 (2011)
Immunodominance and Antigenic Variation of Influenza Virus Hemagglutinin: Implications for Design of Universal Vaccine Immunogens. Zost SJ, Wu NC, Hensley SE, Wilson IA. J Infect Dis 219 S38-S45 (2019)
Influenza mortality in the United States, 2009 pandemic: burden, timing and age distribution. Nguyen AM, Noymer A. PLoS ONE 8 e64198 (2013)
Influenza viral infections among the Iranian Hajj pilgrims returning to Shiraz, Fars province, Iran. Moattari A, Emami A, Moghadami M, Honarvar B. Influenza Other Respir Viruses 6 e77-9 (2012)
The antigenic evolution of influenza: drift or thrift? Wikramaratna PS, Sandeman M, Recker M, Gupta S. Philos. Trans. R. Soc. Lond., B, Biol. Sci. 368 20120200 (2013)
Cryo-electron Microscopy Structures of Chimeric Hemagglutinin Displayed on a Universal Influenza Vaccine Candidate. Tran EE, Podolsky KA, Bartesaghi A, Kuybeda O, Grandinetti G, Wohlbold TJ, Tan GS, Nachbagauer R, Palese P, Krammer F, Subramaniam S. MBio 7 e00257 (2016)
Directed selection of influenza virus produces antigenic variants that match circulating human virus isolates and escape from vaccine-mediated immune protection. DeDiego ML, Anderson CS, Yang H, Holden-Wiltse J, Fitzgerald T, Treanor JJ, Topham DJ. Immunology 148 160-173 (2016)
Heterovariant cross-reactive B-cell responses induced by the 2009 pandemic influenza virus A subtype H1N1 vaccine. He XS, Sasaki S, Baer J, Khurana S, Golding H, Treanor JJ, Topham DJ, Sangster MY, Jin H, Dekker CL, Subbarao K, Greenberg HB. J. Infect. Dis. 207 288-296 (2013)
Longitudinal analysis of the peripheral B cell repertoire reveals unique effects of immunization with a new influenza virus strain. Cortina-Ceballos B, Godoy-Lozano EE, Téllez-Sosa J, Ovilla-Muñoz M, Sámano-Sánchez H, Aguilar-Salgado A, Gómez-Barreto RE, Valdovinos-Torres H, López-Martínez I, Aparicio-Antonio R, Rodríguez MH, Martínez-Barnetche J. Genome Med 7 124 (2015)
Whole genome characterization, phylogenetic and genome signature analysis of human pandemic H1N1 virus in Thailand, 2009-2012. Makkoch J, Suwannakarn K, Payungporn S, Prachayangprecha S, Cheiocharnsin T, Linsuwanon P, Theamboonlers A, Poovorawan Y. PLoS ONE 7 e51275 (2012)
2009 A(H1N1) seroconversion rates and risk factors among the general population in Vientiane Capital, Laos. Kieffer A, Paboriboune P, Crépey P, Flaissier B, Souvong V, Steenkeste N, Salez N, Babin FX, Longuet C, Carrat F, Flahault A, de Lamballerie X. PLoS ONE 8 e61909 (2013)
BlockLogo: visualization of peptide and sequence motif conservation. Olsen LR, Kudahl UJ, Simon C, Sun J, Schönbach C, Reinherz EL, Zhang GL, Brusic V. J. Immunol. Methods 400-401 37-44 (2013)
Discrimination of influenza infection (A/2009 H1N1) from prior exposure by antibody protein microarray analysis. te Beest D, de Bruin E, Imholz S, Wallinga J, Teunis P, Koopmans M, van Boven M. PLoS ONE 9 e113021 (2014)
Influenza A virus acquires enhanced pathogenicity and transmissibility after serial passages in swine. Wei K, Sun H, Sun Z, Sun Y, Kong W, Pu J, Ma G, Yin Y, Yang H, Guo X, Chang KC, Liu J. J. Virol. 88 11981-11994 (2014)
Neutralizing and protective epitopes of the 2009 pandemic influenza H1N1 hemagglutinin. Schmeisser F, Friedman R, Besho J, Lugovtsev V, Soto J, Wang W, Weiss C, Williams O, Xie H, Ye Z, Weir JP. Influenza Other Respir Viruses 7 480-490 (2013)
Planning for the next influenza H1N1 season: a modelling study. Carrat F, Pelat C, Levy-Bruhl D, Bonmarin I, Lapidus N. BMC Infect. Dis. 10 301 (2010)
Putative amino acid determinants of the emergence of the 2009 influenza A (H1N1) virus in the human population. Meroz D, Yoon SW, Ducatez MF, Fabrizio TP, Webby RJ, Hertz T, Ben-Tal N. Proc. Natl. Acad. Sci. U.S.A. 108 13522-13527 (2011)
Seroepidemiologic investigation of an outbreak of pandemic influenza A H1N1 2009 aboard a US Navy vessel--San Diego, 2009. Khaokham CB, Selent M, Loustalot FV, Zarecki SM, Harrington D, Hoke E, Faix DJ, Ortiguerra R, Alvarez B, Almond N, McMullen K, Cadwell B, Uyeki TM, Blair PJ, Waterman SH. Influenza Other Respir Viruses 7 791-798 (2013)
Simple and label-free pathogen enrichment via homobifunctional imidoesters using a microfluidic (SLIM) system for ultrasensitive pathogen detection in various clinical specimens. Jin CE, Koo B, Lee EY, Kim JY, Kim SH, Shin Y. Biosens Bioelectron 111 66-73 (2018)
Surface modifications of influenza proteins upon virus inactivation by β-propiolactone. She YM, Cheng K, Farnsworth A, Li X, Cyr TD. Proteomics 13 3537-3547 (2013)
3-O-galloylated procyanidins from Rumex acetosa L. inhibit the attachment of influenza A virus. Derksen A, Hensel A, Hafezi W, Herrmann F, Schmidt TJ, Ehrhardt C, Ludwig S, Kühn J. PLoS ONE 9 e110089 (2014)
Deciphering and predicting CD4+ T cell immunodominance of influenza virus hemagglutinin. Cassotta A, Paparoditis P, Geiger R, Mettu RR, Landry SJ, Donati A, Benevento M, Foglierini M, Lewis DJM, Lanzavecchia A, Sallusto F. J Exp Med 217 e20200206 (2020)
Genetic diversity of HA1 domain of hemagglutinin gene of pandemic influenza H1N1pdm09 viruses in New Delhi, India. Mir MA, Lal RB, Sullender W, Singh Y, Garten R, Krishnan A, Broor S. J. Med. Virol. 84 386-393 (2012)
IgM, IgG, and IgA antibody responses to influenza A(H1N1)pdm09 hemagglutinin in infected persons during the first wave of the 2009 pandemic in the United States. Li ZN, Lin SC, Carney PJ, Li J, Liu F, Lu X, Liu M, Stevens J, Levine M, Katz JM, Hancock K. Clin. Vaccine Immunol. 21 1054-1060 (2014)
Immunization with 1976 swine H1N1- or 2009 pandemic H1N1-inactivated vaccines protects mice from a lethal 1918 influenza infection. Easterbrook JD, Kash JC, Sheng ZM, Qi L, Gao J, Kilbourne ED, Eichelberger MC, Taubenberger JK. Influenza Other Respir Viruses 5 198-205 (2011)
Insight into structural diversity of influenza virus haemagglutinin. Cho KJ, Lee JH, Hong KW, Kim SH, Park Y, Lee JY, Kang S, Kim S, Yang JH, Kim EK, Seok JH, Unzai S, Park SY, Saelens X, Kim CJ, Lee JY, Kang C, Oh HB, Chung MS, Kim KH. J. Gen. Virol. 94 1712-1722 (2013)
Joint modelling of serological and hospitalization data reveals that high levels of pre-existing immunity and school holidays shaped the influenza A pandemic of 2009 in the Netherlands. Te Beest DE, Birrell PJ, Wallinga J, De Angelis D, van Boven M. J R Soc Interface 12 (2015)
Receptor specificity does not affect replication or virulence of the 2009 pandemic H1N1 influenza virus in mice and ferrets. Lakdawala SS, Shih AR, Jayaraman A, Lamirande EW, Moore I, Paskel M, Kenney H, Sasisekharan R, Subbarao K. Virology 446 349-356 (2013)
Redesigned HIV antibodies exhibit enhanced neutralizing potency and breadth. Willis JR, Sapparapu G, Murrell S, Julien JP, Singh V, King HG, Xia Y, Pickens JA, LaBranche CC, Slaughter JC, Montefiori DC, Wilson IA, Meiler J, Crowe JE. J. Clin. Invest. 125 2523-2531 (2015)
Unusual patterns of IgG avidity in some young children following two doses of the adjuvanted pandemic H1N1 (2009) influenza virus vaccine. Yam KK, Gupta J, Brewer A, Scheifele DW, Halperin S, Ward BJ, Public Health Agency of Canada/Canadian Institute of Health Research, Influenza Research Network (PCIRN) Rapid Trial Study 3 (RT-03) Investigators. Clin. Vaccine Immunol. 20 459-467 (2013)
A pandemic H1N1 influenza virus-like particle vaccine induces cross-protection in mice. Inn KS, Lee GJ, Quan FS. Immunol. Invest. 43 236-254 (2014)
Detection of influenza A virus homo- and heterosubtype-specific memory B-cells using a novel protein microarray-based analysis tool. Baas DC, Koopmans MP, de Bruin E, ten Hulscher HI, Buisman AM, Hendrikx LH, van Beek J, Godeke GJ, Reimerink J, van Binnendijk RS. J. Med. Virol. 85 899-909 (2013)
Intermonomer Interactions in Hemagglutinin Subunits HA1 and HA2 Affecting Hemagglutinin Stability and Influenza Virus Infectivity. Wang W, DeFeo CJ, Alvarado-Facundo E, Vassell R, Weiss CD. J. Virol. 89 10602-10611 (2015)
Monoclonal antibody kit for identification of the novel 2009 H1N1 influenza A virus. Higgins AD, Shaw CJ, Johnson JG, Navarro A, Chapman NA, Ewers SD, Stockwell JW, Carpenter JM, Olivo PD, Miao LY. J. Clin. Microbiol. 48 2677-2682 (2010)
Peptide sharing between influenza A H1N1 hemagglutinin and human axon guidance proteins. Lucchese G, Capone G, Kanduc D. Schizophr Bull 40 362-375 (2014)
Stochastic processes constrain the within and between host evolution of influenza virus. McCrone JT, Woods RJ, Martin ET, Malosh RE, Monto AS, Lauring AS. Elife 7 (2018)
Structural basis and sequence co-evolution analysis of the hemagglutinin protein of pandemic influenza A/H1N1 (2009) virus. Tse H, Kao RY, Wu WL, Lim WW, Chen H, Yeung MY, Woo PC, Sze KH, Yuen KY. Exp. Biol. Med. (Maywood) 236 915-925 (2011)
Amino acid sequence analysis and identification of mutations under positive selection in hemagglutinin of 2009 influenza A (H1N1) isolates. Ding X, Jiang L, Ke C, Yang Z, Lei C, Cao K, Xu J, Xu L, Yang X, Zhang Y, Huang P, Huang W, Zhu X, He Z, Liu L, Li J, Yuan J, Wu J, Tang X, Li M. Virus Genes 41 329-340 (2010)
Changes in heterosubtypic antibody responses during the first year of the 2009 A(H1N1) influenza pandemic. Freidl GS, van den Ham HJ, Boni MF, de Bruin E, Koopmans MP. Sci Rep 6 20385 (2016)
Cross-immunity Against Avian Influenza A(H7N9) Virus in the Healthy Population Is Affected by Antigenicity-Dependent Substitutions. Liu WJ, Tan S, Zhao M, Quan C, Bi Y, Wu Y, Zhang S, Zhang H, Xiao H, Qi J, Yan J, Liu W, Yu H, Shu Y, Wu G, Gao GF. J. Infect. Dis. 214 1937-1946 (2016)
Cross-reactive immunity against influenza viruses in children and adults following 2009 pandemic H1N1 infection. Ahmed MS, Jacques LC, Mahallawi W, Ferrara F, Temperton N, Upile N, Vaughan C, Sharma R, Beer H, Hoschler K, McNamara PS, Zhang Q. Antiviral Res. 114 106-112 (2015)
Diagnosis and antiviral intervention strategies for mitigating an influenza epidemic. Moss R, McCaw JM, McVernon J. PLoS ONE 6 e14505 (2011)
Emerging antigenic variants at the antigenic site Sb in pandemic A(H1N1)2009 influenza virus in Japan detected by a human monoclonal antibody. Yasugi M, Kubota-Koketsu R, Yamashita A, Kawashita N, Du A, Misaki R, Kuhara M, Boonsathorn N, Fujiyama K, Okuno Y, Nakaya T, Ikuta K. PLoS ONE 8 e77892 (2013)
H1N1 viral proteome peptide microarray predicts individuals at risk for H1N1 infection and segregates infection versus Pandemrix(®) vaccination. Ambati A, Valentini D, Montomoli E, Lapini G, Biuso F, Wenschuh H, Magalhaes I, Maeurer M. Immunology 145 357-366 (2015)
Infection with 2009 H1N1 influenza virus primes for immunological memory in human nose-associated lymphoid tissue, offering cross-reactive immunity to H1N1 and avian H5N1 viruses. Mahallawi WH, Kasbekar AV, McCormick MS, Hoschler K, Temperton N, Leong SC, Beer H, Ferrara F, McNamara PS, Zhang Q. J. Virol. 87 5331-5339 (2013)
Isolation of a high affinity neutralizing monoclonal antibody against 2009 pandemic H1N1 virus that binds at the 'Sa' antigenic site. Shembekar N, Mallajosyula VV, Mishra A, Yeolekar L, Dhere R, Kapre S, Varadarajan R, Gupta SK. PLoS ONE 8 e55516 (2013)
Persistence of pandemic influenza H1N1 virus in young patients after oseltamivir therapy in the 2009-2010 season: a comparison with seasonal H1N1 with or without H275Y mutation. Kawai N, Ikematsu H, Iwaki N, Kondou K, Hirotsu N, Kawashima T, Maeda T, Tanaka O, Doniwa K, Iwakuni O, Egashira K, Yamaji K, Kashiwagi S. J. Infect. Chemother. 18 180-186 (2012)
Pre-existing immunity with high neutralizing activity to 2009 pandemic H1N1 influenza virus in Shanghai population. Liu X, Liu Y, Zhang Y, Chen Z, Tang Z, Xu Q, Wang Y, Zhao P, Qi Z. PLoS ONE 8 e58810 (2013)
Characterization of Influenza Vaccine Hemagglutinin Complexes by Cryo-Electron Microscopy and Image Analyses Reveals Structural Polymorphisms. McCraw DM, Gallagher JR, Harris AK. Clin. Vaccine Immunol. 23 483-495 (2016)
Characterization of an enhanced antigenic change in the pandemic 2009 H1N1 influenza virus haemagglutinin. García-Barreno B, Delgado T, Benito S, Casas I, Pozo F, Cuevas MT, Mas V, Trento A, Rodriguez-Frandsen A, Falcón A, Ortín J, Nieto A, Melero JA. J. Gen. Virol. 95 1033-1042 (2014)
Cross reactivity of serum antibody responses elicited by DNA vaccines expressing HA antigens from H1N1 subtype influenza vaccines in the past 30 years. Almansour I, Chen H, Wang S, Lu S. Hum Vaccin Immunother 9 2049-2059 (2013)
Evolution of the hemagglutinin expressed by human influenza A(H1N1)pdm09 and A(H3N2) viruses circulating between 2008-2009 and 2013-2014 in Germany. Wedde M, Biere B, Wolff T, Schweiger B. Int. J. Med. Microbiol. 305 762-775 (2015)
Insight into highly conserved H1 subtype-specific epitopes in influenza virus hemagglutinin. Cho KJ, Hong KW, Kim SH, Seok JH, Kim S, Lee JH, Saelens X, Kim KH. PLoS ONE 9 e89803 (2014)
Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies. Pardi N, Parkhouse K, Kirkpatrick E, McMahon M, Zost SJ, Mui BL, Tam YK, Karikó K, Barbosa CJ, Madden TD, Hope MJ, Krammer F, Hensley SE, Weissman D. Nat Commun 9 3361 (2018)
Principles underlying rational design of live attenuated influenza vaccines. Jang YH, Seong BL. Clin Exp Vaccine Res 1 35-49 (2012)
The dynamics of infection and the persistence of immunity to A(H1N1)pdm09 virus in Israel. Weil M, Shohat T, Bromberg M, Bassal R, Dichtiar R, Mandelboim M, Sofer D, Cohen D, Mendelson E. Influenza Other Respir Viruses 7 838-846 (2013)
The nonadaptive nature of the H1N1 2009 Swine Flu pandemic contrasts with the adaptive facilitation of transmission to a new host. Abdussamad J, Aris-Brosou S. BMC Evol. Biol. 11 6 (2011)
A naturally protective epitope of limited variability as an influenza vaccine target. Thompson CP, Lourenço J, Walters AA, Obolski U, Edmans M, Palmer DS, Kooblall K, Carnell GW, O'Connor D, Bowden TA, Pybus OG, Pollard AJ, Temperton NJ, Lambe T, Gilbert SC, Gupta S. Nat Commun 9 3859 (2018)
Characterization of antibodies specific for hemagglutinin and neuraminidase proteins of the 1918 and 2009 pandemic H1N1 viruses. Liu Y, Liu X, Fang J, Shen X, Chen W, Lin X, Li H, Tan W, Wang Y, Zhao P, Qi Z. Vaccine 29 183-190 (2010)
Letter Lower mortality from H1N1 influenza in older Argentineans: men more affected. Roriz-Cruz M, Rosset I, Montero-Odasso M. J Am Geriatr Soc 58 1813-1815 (2010)
Molecular modeling, docking and dynamics simulations of GNA-related lectins for potential prevention of influenza virus (H1N1). Xu HL, Li CY, He XM, Niu KQ, Peng H, Li WW, Zhou CC, Bao JK. J Mol Model 18 27-37 (2012)
N-linked glycans on influenza A H3N2 hemagglutinin constrain binding of host antibodies, but shielding is limited. Pentiah K, Lees WD, Moss DS, Shepherd AJ. Glycobiology 25 124-132 (2015)
Phylogenetic analysis of pandemic 2009 influenza A virus circulating in the South American region: genetic relationships and vaccine strain match. Goñi N, Moratorio G, Ramas V, Coppola L, Chiparelli H, Cristina J. Arch. Virol. 156 87-94 (2011)
Prevalence and predictors for homo- and heterosubtypic antibodies against influenza a virus. Kohler I, Scherrer AU, Zagordi O, Bianchi M, Wyrzucki A, Steck M, Ledergerber B, Günthard HF, Hangartner L. Clin. Infect. Dis. 59 1386-1393 (2014)
Transient humoral protection against H5N1 challenge after seasonal influenza vaccination of humans. Roozendaal R, Tolboom J, Roos A, Riahi S, Theeuwsen J, Bujny MV, Klaren V, Korse HJ, Dekking L, Grootenhuis A, Weverling GJ, Koudstaal W, Goudsmit J, Radošević K. PLoS ONE 9 e103550 (2014)
A Highly Potent and Broadly Neutralizing H1 Influenza-Specific Human Monoclonal Antibody. Nogales A, Piepenbrink MS, Wang J, Ortega S, Basu M, Fucile CF, Treanor JJ, Rosenberg AF, Zand MS, Keefer MC, Martinez-Sobrido L, Kobie JJ. Sci Rep 8 4374 (2018)
Absence of cross-reactive antibodies to influenza A (H1N1) 2009 before and after vaccination with 2009 Southern Hemisphere seasonal trivalent influenza vaccine in children aged 6 months-9 years: a prospective study. McVernon J, Laurie K, Barr I, Kelso A, Skeljo M, Nolan T. Influenza Other Respir Viruses 5 7-11 (2011)
Association analyses of large-scale glycan microarray data reveal novel host-specific substructures in influenza A virus binding glycans. Zhao N, Martin BE, Yang CK, Luo F, Wan XF. Sci Rep 5 15778 (2015)
Dynamics of an SEQIHRS epidemic model with media coverage, quarantine and isolation in a community with pre-existing immunity. Sahu GP, Dhar J. J Math Anal Appl 421 1651-1672 (2015)
Emergence of Hemagglutinin Mutations During the Course of Influenza Infection. Cushing A, Kamali A, Winters M, Hopmans ES, Bell JM, Grimes SM, Xia LC, Zhang NR, Moss RB, Holodniy M, Ji HP. Sci Rep 5 16178 (2015)
Feature selection methods for identifying genetic determinants of host species in RNA viruses. Aguas R, Ferguson NM. PLoS Comput. Biol. 9 e1003254 (2013)
Glycosylation of Residue 141 of Subtype H7 Influenza A Hemagglutinin (HA) Affects HA-Pseudovirus Infectivity and Sensitivity to Site A Neutralizing Antibodies. Alvarado-Facundo E, Vassell R, Schmeisser F, Weir JP, Weiss CD, Wang W. PLoS ONE 11 e0149149 (2016)
H1N1pdm09 adjuvanted vaccination in HIV-infected adults: a randomized trial of two single versus two double doses. Santini-Oliveira M, Camacho LA, Souza TM, Luz PM, Vasconcellos MT, Giacoia-Gripp CB, Morgado MG, Nunes EP, Lemos AS, Ferreira AC, Moreira RI, Veloso VG, Siqueira MM, Grinsztejn B. PLoS ONE 7 e39310 (2012)
Individual antibody and T cell responses to vaccination and infection with the 2009 pandemic swine-origin H1N1 influenza virus. Air GM, Feng J, Chen T, Joachims ML, James JA, Thompson LF. J. Clin. Immunol. 31 900-912 (2011)
Influenza virus surveillance using surface plasmon resonance. Suenaga E, Mizuno H, Kumar PK. Virulence 3 464-470 (2012)
Molecular docking analysis of 2009-H1N1 and 2004-H5N1 influenza virus HLA-B*4405-restricted HA epitope candidates: implications for TCR cross-recognition and vaccine development. Su CT, Schönbach C, Kwoh CK. BMC Bioinformatics 14 Suppl 2 S21 (2013)
Parameter identification for a stochastic SEIRS epidemic model: case study influenza. Mummert A, Otunuga OM. J Math Biol 79 705-729 (2019)
Predicting the Mutating Distribution at Antigenic Sites of the Influenza Virus. Xu H, Yang Y, Wang S, Zhu R, Qiu T, Qiu J, Zhang Q, Jin L, He Y, Tang K, Cao Z. Sci Rep 6 20239 (2016)
The antigenic property of the H5N1 avian influenza viruses isolated in central China. Zou W, Ke J, Zhu J, Zhou H, Jin M. Virol. J. 9 148 (2012)
The impact of vaccination on the breadth and magnitude of the antibody response to influenza A viruses in HIV-infected individuals. Kohler I, Kouyos R, Bianchi M, Grube C, Wyrzucki A, Günthard HF, Hangartner L. AIDS 29 1803-1810 (2015)
Letter Unmasking masks in Makkah: preventing influenza at Hajj. Rashid H, Booy R, Heron L, Memish ZA, Nguyen-Van-Tam J, Barasheed O, Haworth E. Clin. Infect. Dis. 54 151-153 (2012)
A hybrid EM and Monte Carlo EM algorithm and its application to analysis of transmission of infectious diseases. Yang Y, Longini IM, Halloran ME, Obenchain V. Biometrics 68 1238-1249 (2012)
Antibody Determinants of Influenza Immunity. Crowe JE. J Infect Dis 219 S21-S29 (2019)
Antigenic drift of hemagglutinin and neuraminidase in seasonal H1N1 influenza viruses from Saudi Arabia in 2014 to 2015. Naeem A, Elbakkouri K, Alfaiz A, Hamed ME, Alsaran H, AlOtaiby S, Enani M, Alosaimi B. J Med Virol (2020)
Changes to the dynamic nature of hemagglutinin and the emergence of the 2009 pandemic H1N1 influenza virus. Yoon SW, Chen N, Ducatez MF, McBride R, Barman S, Fabrizio TP, Webster RG, Haliloglu T, Paulson JC, Russell CJ, Hertz T, Ben-Tal N, Webby RJ. Sci Rep 5 12828 (2015)
Estimating Direct and Indirect Protective Effect of Influenza Vaccination in the United States. Arinaminpathy N, Kim IK, Gargiullo P, Haber M, Foppa IM, Gambhir M, Bresee J. Am. J. Epidemiol. 186 92-100 (2017)
Extreme evolutionary conservation of functionally important regions in H1N1 influenza proteome. Warren S, Wan XF, Conant G, Korkin D. PLoS ONE 8 e81027 (2013)
Human Monoclonal Antibody Derived from Transchromosomic Cattle Neutralizes Multiple H1 Clades of Influenza A Virus by Recognizing a Novel Conformational Epitope in the Hemagglutinin Head Domain. Gao R, Sreenivasan CC, Sheng Z, Hause BM, Zhou B, Wentworth DE, Clement T, Rausch D, Brunick C, Christopher-Hennings J, Wu H, Bausch CL, Sullivan EJ, Hoppe AD, Huber VC, Wang D, Li F. J Virol 94 e00945-20 (2020)
Human antibody 3E1 targets the HA stem region of H1N1 and H5N6 influenza A viruses. Wang W, Sun X, Li Y, Su J, Ling Z, Zhang T, Wang F, Zhang H, Chen H, Ding J, Sun B. Nat Commun 7 13577 (2016)
Impact of influenza virus escape-mutations on influenza detection by the rapid influenza diagnostic test. Yi H, Kim YH, Kim JS, Lee NJ, Shin K, Choi JH, Kwon D, Lee JY, Kang C. J. Med. Virol. 85 709-715 (2013)
Infections with A(H1N1)2009 influenza virus in Poland during the last pandemic: experience of the National Influenza Center. Romanowska M, Stefanska I, Donevski S, Brydak LB. Adv. Exp. Med. Biol. 756 271-283 (2013)
Influence of Birth Cohort on Effectiveness of 2015-2016 Influenza Vaccine Against Medically Attended Illness Due to 2009 Pandemic Influenza A(H1N1) Virus in the United States. Flannery B, Smith C, Garten RJ, Levine MZ, Chung JR, Jackson ML, Jackson LA, Monto AS, Martin ET, Belongia EA, McLean HQ, Gaglani M, Murthy K, Zimmerman R, Nowalk MP, Griffin MR, Keipp Talbot H, Treanor JJ, Wentworth DE, Fry AM. J. Infect. Dis. 218 189-196 (2018)
Influenza A HA's conserved epitopes and broadly neutralizing antibodies: a prediction method. Ren J, Ellis J, Li J. J Bioinform Comput Biol 12 1450023 (2014)
Refining the approach to vaccines against influenza A viruses with pandemic potential. Czako R, Subbarao K. Future Virol 10 1033-1047 (2015)
Site-specific glycosylation profile of influenza A (H1N1) hemagglutinin through tandem mass spectrometry. Cruz E, Cain J, Crossett B, Kayser V. Hum Vaccin Immunother 14 508-517 (2018)
Structural Insight into a Human Neutralizing Antibody against Influenza Virus H7N9. Chen C, Liu L, Xiao Y, Cui S, Wang J, Jin Q. J. Virol. 92 (2018)
Structural analysis of the hot spots in the binding between H1N1 HA and the 2D1 antibody: do mutations of H1N1 from 1918 to 2009 affect much on this binding? Liu Q, Hoi SC, Su CT, Li Z, Kwoh CK, Wong L, Li J. Bioinformatics 27 2529-2536 (2011)
Swine-origin influenza-virus-induced acute lung injury: Novel or classical pathogenesis? Maeda N, Uede T. World J Biol Chem 1 85-94 (2010)
Topological N-glycosylation and site-specific N-glycan sulfation of influenza proteins in the highly expressed H1N1 candidate vaccines. She YM, Farnsworth A, Li X, Cyr TD. Sci Rep 7 10232 (2017)
Virological surveillance of influenza and other respiratory viruses during six consecutive seasons from 2006 to 2012 in Catalonia, Spain. Antón A, Marcos MA, Torner N, Isanta R, Camps M, Martínez A, Domínguez A, Jané M, Jiménez de Anta MT, Pumarola T. Clin. Microbiol. Infect. 22 564.e1-9 (2016)
A small-molecule fusion inhibitor of influenza virus is orally active in mice. van Dongen MJP, Kadam RU, Juraszek J, Lawson E, Brandenburg B, Schmitz F, Schepens WBG, Stoops B, van Diepen HA, Jongeneelen M, Tang C, Vermond J, van Eijgen-Obregoso Real A, Blokland S, Garg D, Yu W, Goutier W, Lanckacker E, Klap JM, Peeters DCG, Wu J, Buyck C, Jonckers THM, Roymans D, Roevens P, Vogels R, Koudstaal W, Friesen RHE, Raboisson P, Dhanak D, Goudsmit J, Wilson IA. Science 363 (2019)
Age-specific effects of vaccine egg adaptation and immune priming on A(H3N2) antibody responses following influenza vaccination. Liu F, Gross FL, Jefferson SN, Holiday C, Bai Y, Wang L, Zhou B, Levine MZ. J Clin Invest 131 146138 (2021)
Antibody responses to avian influenza viruses in wild birds broaden with age. Hill SC, Manvell RJ, Schulenburg B, Shell W, Wikramaratna PS, Perrins C, Sheldon BC, Brown IH, Pybus OG. Proc. Biol. Sci. 283 (2016)
Computational studies of pandemic 1918 and 2009 H1N1 hemagglutinins bound to avian and human receptor analogs. Kannan S, Kolandaivel P. J. Biomol. Struct. Dyn. 34 272-289 (2016)
Echoes of 2009 H1N1 Influenza Pandemic in the COVID Pandemic. Jhaveri R. Clin Ther 42 736-740 (2020)
INFLUENZA SURVEILLANCE IN RUSSIA BASED ON EPIDEMIOLOGICAL AND LABORATORY DATA FOR THE PERIOD FROM 2005 TO 2012. Anna S, Burtseva E, Eropkin M, Karpova L, Zarubaev V, Smorodintseva E, Konovalova N, Danilenko D, Prokopetz A, Grudinin M, Pisareva M, Anfimov P, Stolyarov K, Kiselev O, Shevchenko E, Ivanova V, Trushakova S, Breslav N, Lvov D, Klimov A, Moen A, Cox N. Am J Infect Dis 9 77-93 (2013)
Influenza-attributable deaths in south-eastern France (1999 to 2010): mortality predictions were undependable. Thiberville SD, Gaudart J, Raoult D, Charrel RN. BMC Public Health 15 539 (2015)
Laninamivir-Interferon Lambda 1 Combination Treatment Promotes Resistance by Influenza A Virus More Rapidly than Laninamivir Alone. Adams SE, Lugovtsev VY, Kan A, Bovin NV, Donnelly RP, Ilyushina NA. Antimicrob Agents Chemother 64 e00301-20 (2020)
Mesoscale All-Atom Influenza Virus Simulations Suggest New Substrate Binding Mechanism. Durrant JD, Kochanek SE, Casalino L, Ieong PU, Dommer AC, Amaro RE. ACS Cent Sci 6 189-196 (2020)
Molecular and phylogenetic analysis of influenza A H1N1 pandemic viruses in Cuba, May 2009 to August 2010. Ramos AP, Herrera BA, Ramírez OV, García AA, Jiménez MM, Valdés CS, Fernández AG, González G, Fernández SI, Báez GG, Espinosa BH. Int. J. Infect. Dis. 17 e565-7 (2013)
Molecular epidemiology of influenza A virus infection among hospitalized children in Vietnam during post-pandemic period. Tran DN, Pham TM, Ha MT, Hayakawa S, Mizuguchi M, Ushijima H. J. Med. Virol. 87 904-912 (2015)
Molecular influenza surveillance at a tertiary university hospital during four consecutive seasons (2012-2016) in Catalonia, Spain. Andrés C, Peremiquel-Trillas P, Gimferrer L, Piñana M, Codina MG, Rodrigo-Pendás JÁ, Campins-Martí M, Carmen Martín M, Fuentes F, Rubio S, Pumarola T, Antón A. Vaccine 37 2470-2476 (2019)
Prevalence of neutralizing antibodies to common respiratory viruses in intravenous immunoglobulin and in healthy donors in southern China. Tian X, Jiang Z, Ma Q, Liu Q, Lu X, Liu W, Liao X, Zhou R, Su X, Luo Q. J Thorac Dis 8 803-812 (2016)
Q&A: H1N1 pandemic influenza--what's new? Turner SJ, Doherty PC, Kelso A. BMC Biol. 8 130 (2010)
Reliability of pseudotyped influenza viral particles in neutralizing antibody detection. Yang J, Li W, Long Y, Song S, Liu J, Zhang X, Wang X, Jiang S, Liao G. PLoS ONE 9 e113629 (2014)
Seroprevalence study of antibodies against influenza A(H1N1) 2009 virus after the second pandemic wave in Slovenia. Subelj V, Prosenc K, Sočan M. Wien. Klin. Wochenschr. 124 177-180 (2012)
Similarity of currently circulating H1N1 virus with the 2009 pandemic clone: viability of an imminent pandemic. Banerjee R, Roy A, Das S, Basak S. Infect. Genet. Evol. 32 107-112 (2015)
Two different genotypes of H1N2 swine influenza virus isolated in northern China and their pathogenicity in animals. Yang H, Chen Y, Qiao C, Xu C, Yan M, Xin X, Bu Z, Chen H. Vet. Microbiol. 175 224-231 (2015)
A continuous peptide epitope reacting with pandemic influenza AH1N1 predicted by bioinformatic approaches. Carrillo-Vazquez JP, Correa-Basurto J, García-Machorro J, Campos-Rodríguez R, Moreau V, Rosas-Trigueros JL, Reyes-López CA, Rojas-López M, Zamorano-Carrillo A. J. Mol. Recognit. 28 553-564 (2015)
Association between Haemagglutination inhibiting antibodies and protection against clade 6B viruses in 2013 and 2015. Ng S, Saborio S, Kuan G, Gresh L, Sanchez N, Ojeda S, Harris E, Balmaseda A, Gordon A. Vaccine 35 6202-6207 (2017)
Bayesian coalescent analysis of pandemic H1N1 influenza A virus circulating in the South American region. Goñi N, Moratorio G, Coppola L, Ramas V, Comas V, Soñora M, Chiparelli H, Cristina J. Virus Res. 170 91-101 (2012)
Bioinformatics design and experimental validation of influenza A virus multi-epitopes that induce neutralizing antibodies. Ramírez-Salinas GL, García-Machorro J, Rojas-Hernández S, Campos-Rodríguez R, de Oca AC, Gomez MM, Luciano R, Zimic M, Correa-Basurto J. Arch Virol 165 891-911 (2020)
Broad neutralizing activity of a human monoclonal antibody against H7N9 strains from 2013 to 2017. Chen C, Liu Z, Liu L, Xiao Y, Wang J, Jin Q. Emerg Microbes Infect 7 179 (2018)
COVID-19-Related Age Profiles for SARS-CoV-2 Variants in England and Wales and States of the USA (2020 to 2022): Impact on All-Cause Mortality. Jones RP, Ponomarenko A. Infect Dis Rep 15 600-634 (2023)
Capturing the inherent structural dynamics of the HIV-1 envelope glycoprotein fusion peptide. Kumar S, Sarkar A, Pugach P, Sanders RW, Moore JP, Ward AB, Wilson IA. Nat Commun 10 763 (2019)
Comparison of the characteristics of elderly influenza patients in two consecutive seasons. Lee SS, To KW, Wong NS, Choi KW, Lee KC. Int. J. Infect. Dis. 24 40-42 (2014)
Conformational Stability of the Hemagglutinin of H5N1 Influenza A Viruses Influences Susceptibility to Broadly Neutralizing Stem Antibodies. Wang W, Song HS, Keller PW, Alvarado-Facundo E, Vassell R, Weiss CD. J. Virol. 92 (2018)
Conformational modulation of influenza virus hemagglutinin: characterization and in vivo efficacy of monomeric form. Seok JH, Kim J, Lee DB, Cho KJ, Lee JH, Bae G, Chung MS, Kim KH. Sci Rep 7 7540 (2017)
Detection of the influenza A(H1N1)pdm09 virus carrying the K-15E, P83S and Q293H mutations in patients who have undergone bone marrow transplant. Mesquita M, Resende P, Marttorelli A, Machado V, Sacramento CQ, Fintelman-Rodrigues N, Abrantes JL, Tavares R, Schirmer M, Siqueira MM, Souza TM. PLoS ONE 9 e94822 (2014)
Discovery of New Ginsenol-Like Compounds with High Antiviral Activity. Volobueva AS, Yarovaya OI, Kireeva MV, Borisevich SS, Kovaleva KS, Mainagashev IY, Gatilov YV, Ilyina MG, Zarubaev VV, Salakhutdinov NF. Molecules 26 6794 (2021)
Diversity of antigenic mutants of influenza A(H1N1)pdm09 virus escaped from human monoclonal antibodies. Yasuhara A, Yamayoshi S, Soni P, Takenaga T, Kawakami C, Takashita E, Sakai-Tagawa Y, Uraki R, Ito M, Iwatsuki-Horimoto K, Sasaki T, Ikuta K, Yamada S, Kawaoka Y. Sci Rep 7 17735 (2017)
Glycosylation of Hemagglutinin and Neuraminidase of Influenza A Virus as Signature for Ecological Spillover and Adaptation among Influenza Reservoirs. Kim P, Jang YH, Kwon SB, Lee CM, Han G, Seong BL. Viruses 10 (2018)
H5N1 influenza vaccine induces a less robust neutralizing antibody response than seasonal trivalent and H7N9 influenza vaccines. Wong SS, DeBeauchamp J, Zanin M, Sun Y, Tang L, Webby R. NPJ Vaccines 2 16 (2017)
Immunity against influenza A(H1N1) infections is determined by age at the time of initial strain circulation. Delabre RM, Salez N, Lapidus N, Lemaitre M, Leruez-Ville M, de Lamballerie X, Carrat F. Epidemiol Infect 145 141-147 (2017)
Insights into structural and inhibitory mechanisms of low pH-induced conformational change of influenza HA2 protein: a computational approach. Kannan S, Shankar R, Kolandaivel P. J Mol Model 25 99 (2019)
Microbial Cryptotopes are Prominent Targets of B-cell Immunity. Rieder FJ, Biebl J, Kastner MT, Schneider M, Jungbauer C, Redlberger-Fritz M, Britt WJ, Kundi M, Steininger C. Sci Rep 6 31657 (2016)
Molecular dynamics studies of human receptor molecule in hemagglutinin of 1918 and 2009 H1N1 influenza viruses. Lee AN, Hartono YD, Sun T, Leow ML, Liu XW, Huang X, Zhang D. J Mol Model 17 1635-1641 (2011)
Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses. Kanekiyo M, Joyce MG, Gillespie RA, Gallagher JR, Andrews SF, Yassine HM, Wheatley AK, Fisher BE, Ambrozak DR, Creanga A, Leung K, Yang ES, Boyoglu-Barnum S, Georgiev IS, Tsybovsky Y, Prabhakaran MS, Andersen H, Kong WP, Baxa U, Zephir KL, Ledgerwood JE, Koup RA, Kwong PD, Harris AK, McDermott AB, Mascola JR, Graham BS. Nat. Immunol. 20 362-372 (2019)
New genetic variants of influenza A(H1N1)pdm09 detected in Cuba during 2011-2013. Arencibia A, Acosta B, Muné M, Valdés O, Fernandez L, Medina I, Savón C, Oropesa S, Gonzalez G, Roque R, Gonzalez G, Hernández B, Goyenechea A, Piñón A. Infect. Genet. Evol. 32 322-326 (2015)
Obesity Is Associated with an Impaired Baseline Repertoire of Anti-Influenza Virus Antibodies. Abd Alhadi M, Friedman LM, Karlsson EA, Cohen-Lavi L, Burkovitz A, Schultz-Cherry S, Noah TL, Weir SS, Shulman LM, Beck MA, Hertz T. Microbiol Spectr 11 e0001023 (2023)
Proteomics study of N-acetylcysteine response in H1N1-infected cells by using mass spectrometry. Wu H, Song W, Gao X, Liu N, Wang P, Chen H, Cai Z. Rapid Commun. Mass Spectrom. 28 741-749 (2014)
Return and reformation after a century -- from 1918 to 2009 H1N1. Zhang X. Protein Cell 1 425-426 (2010)
Rules of co-occurring mutations characterize the antigenic evolution of human influenza A/H3N2, A/H1N1 and B viruses. Chen H, Zhou X, Zheng J, Kwoh CK. BMC Med Genomics 9 69 (2016)
Sequence analysis of haemagglutinin and neuraminidase of H1N1 strain from a patient coinfected with Mycobacterium tuberculosis. Alghamdi AN, Mahfouz ME, Hamdi FA, Al Aboud D, Al-Laylah TZ, Alotaibi MI, Al-Thomali KWA, Abdel-Moneim AS. Mol. Cell. Probes 34 59-63 (2017)
Site-specific glycan analysis of the SARS-CoV-2 spike. Watanabe Y, Allen JD, Wrapp D, McLellan JS, Crispin M. Science 369 330-333 (2020)
Letter Sporadic human cases of swine-origin influenza before 2009 share the Sa epitope. Maurer-Stroh S, Paing SS, Lee RT, Eisenhaber F. Cell Cycle 9 3826-3828 (2010)
Structural and functional definition of a vulnerable site on the hemagglutinin of highly pathogenic avian influenza A virus H5N1. Wang P, Zuo Y, Sun J, Zuo T, Zhang S, Guo S, Shi X, Liang M, Zhou P, Zhang L, Wang X. J. Biol. Chem. 294 4290-4303 (2019)
Structure-Guided Creation of an Anti-HA Stalk Antibody F11 Derivative That Neutralizes Both F11-Sensitive and -Resistant Influenza A(H1N1)pdm09 Viruses. Kotani O, Suzuki Y, Saito S, Ainai A, Ueno A, Hemmi T, Sano K, Tabata K, Yokoyama M, Suzuki T, Hasegawa H, Sato H. Viruses 13 1733 (2021)
The emergence and evolution of influenza A (H1α) viruses in swine in Canada and the United States. Nelson MI, Culhane MR, Trovão NS, Patnayak DP, Halpin RA, Lin X, Shilts MH, Das SR, Detmer SE. J. Gen. Virol. 98 2663-2675 (2017)
The role of human immunity and social behavior in shaping influenza evolution. Kucharski AJ, Baguelin M. PLoS Pathog. 13 e1006432 (2017)
Triterpenoids manipulate a broad range of virus-host fusion via wrapping the HR2 domain prevalent in viral envelopes. Si L, Meng K, Tian Z, Sun J, Li H, Zhang Z, Soloveva V, Li H, Fu G, Xia Q, Xiao S, Zhang L, Zhou D. Sci Adv 4 eaau8408 (2018)
VarEPS-Influ:an risk evaluation system of occurred and virtual variations of influenza virus genomes. Shu C, Sun Q, Fan G, Peng K, Yu Z, Luo Y, Gao S, Ma J, Deng T, Hu S, Wu L. Nucleic Acids Res 52 D798-D807 (2024)
Virus purification and enrichment by hydroxyapatite chromatography on a chip. Niimi M, Masuda T, Kaihatsu K, Kato N, Nakamura S, Nakaya T, Arai F. Sens Actuators B Chem 201 185-190 (2014)
A Coarse-Grained Model of Affinity Maturation Indicates the Importance of B-Cell Receptor Avidity in Epitope Subdominance. Ovchinnikov V, Karplus M. Front Immunol 13 816634 (2022)
A systematic review and meta-analysis of cross-reactivity of antibodies induced by H7 influenza vaccine. Gou X, Wu X, Shi Y, Zhang K, Huang J. Hum Vaccin Immunother 16 286-294 (2020)
An Effective Neutralizing Antibody Against Influenza Virus H1N1 from Human B Cells. Lee CC, Yang CY, Lin LL, Ko TP, Chang AH, Chang SS, Wang AH. Sci Rep 9 4546 (2019)
An Influenza Virus Hemagglutinin-Based Vaccine Platform Enables the Generation of Epitope Specific Human Cytomegalovirus Antibodies. Behzadi MA, Stein KR, Bermúdez-González MC, Simon V, Nachbagauer R, Tortorella D. Vaccines (Basel) 7 (2019)
Analysis of multi-strain infection of vaccinated and recovered population through epidemic model: Application to COVID-19. Otunuga OM. PLoS One 17 e0271446 (2022)
Association of VH4-59 Antibody Variable Gene Usage with Recognition of an Immunodominant Epitope on the HIV-1 Gag Protein. Chukwuma VU, Hicar MD, Chen X, Nicholas KJ, Joyner A, Kalams SA, Landucci G, Forthal DN, Spearman PW, Crowe JE. PLoS ONE 10 e0133509 (2015)
Editorial Back to the future with influenza. Griffiths PD. Rev. Med. Virol. 20 263-264 (2010)
Bioinformatics and Structural Analysis of Antigenic Variation in the Hemagglutinin Gene of the Influenza A(H1N1)pdm09 Virus Circulating in Shiraz (2013 to 2015). Mortazavi M, Pirbonyeh N, Javanmardi F, Emami A. Microbiol Spectr 11 e0463022 (2023)
Breathing and Tilting: Mesoscale Simulations Illuminate Influenza Glycoprotein Vulnerabilities. Casalino L, Seitz C, Lederhofer J, Tsybovsky Y, Wilson IA, Kanekiyo M, Amaro RE. ACS Cent Sci 8 1646-1663 (2022)
Characterization of Influenza A(H1N1)pdm09 Viruses Isolated in the 2018-2019 and 2019-2020 Influenza Seasons in Japan. Soga T, Duong C, Pattinson D, Sakai-Tagawa Y, Tokita A, Izumida N, Nishino T, Hagiwara H, Wada N, Miyamoto Y, Kuroki H, Hayashi Y, Seki M, Kasuya N, Koga M, Adachi E, Iwatsuki-Horimoto K, Yotsuyanagi H, Yamayoshi S, Kawaoka Y. Viruses 15 535 (2023)
Childhood immune imprinting to influenza A shapes birth year-specific risk during seasonal H1N1 and H3N2 epidemics. Gostic KM, Bridge R, Brady S, Viboud C, Worobey M, Lloyd-Smith JO. PLoS Pathog. 15 e1008109 (2019)
Comparative Immunogenicity of Bacterially Expressed Soluble Trimers and Nanoparticle Displayed Influenza Hemagglutinin Stem Immunogens. Kar U, Khaleeq S, Garg P, Bhat M, Reddy P, Vignesh VS, Upadhyaya A, Das M, Chakshusmathi G, Pandey S, Dutta S, Varadarajan R. Front Immunol 13 890622 (2022)
Comparison of the Protective Efficacy of Neutralizing Epitopes of 2009 Pandemic H1N1 Influenza Hemagglutinin. Peng B, Peng N, Zhang Y, Zhang F, Li X, Chang H, Fang F, Wang F, Lu F, Chen Z. Front Immunol 8 1070 (2017)
Computationally optimized broadly reactive vaccine based upon swine H1N1 influenza hemagglutinin sequences protects against both swine and human isolated viruses. Skarlupka AL, Owino SO, Suzuki-Williams LP, Crevar CJ, Carter DM, Ross TM. Hum Vaccin Immunother 15 2013-2029 (2019)
Conserved topology of virus glycoepitopes presents novel targets for repurposing HIV antibody 2G12. Miller NL, Subramanian V, Clark T, Raman R, Sasisekharan R. Sci Rep 12 2594 (2022)
Convergent Evolution in Breadth of Two VH6-1-Encoded Influenza Antibody Clonotypes from a Single Donor. Wu NC, Andrews SF, Raab JE, O'Connell S, Schramm CA, Ding X, Chambers MJ, Leung K, Wang L, Zhang Y, Mascola JR, Douek DC, Ledgerwood JE, McDermott AB, Wilson IA. Cell Host Microbe 28 434-444.e4 (2020)
Development of PREDAC-H1pdm to model the antigenic evolution of influenza A/(H1N1) pdm09 viruses. Liu M, Liu J, Song W, Peng Y, Ding X, Deng L, Jiang T. Virol Sin 38 541-548 (2023)
Development of molecular clamp stabilized hemagglutinin vaccines for Influenza A viruses. McMillan CLD, Cheung STM, Modhiran N, Barnes J, Amarilla AA, Bielefeldt-Ohmann H, Lee LYY, Guilfoyle K, van Amerongen G, Stittelaar K, Jakob V, Lebas C, Reading P, Short KR, Young PR, Watterson D, Chappell KJ. NPJ Vaccines 6 135 (2021)
Effect of pH on the hinge region of influenza viral protein: a combined constant pH and well-tempered molecular dynamics study. Pathak AK. J Phys Condens Matter 30 195101 (2018)
Epistasis reduces fitness costs of influenza A virus escape from stem-binding antibodies. Lee CY, Raghunathan V, Caceres CJ, Geiger G, Seibert B, Cargnin Faccin F, Gay LC, Ferreri LM, Kaul D, Wrammert J, Tan GS, Perez DR, Lowen AC. Proc Natl Acad Sci U S A 120 e2208718120 (2023)
Evolution of Indian Influenza A (H1N1) Hemagglutinin Strains: A Comparative Analysis of the Pandemic Californian HA Strain. Pushan SS, Samantaray M, Rajagopalan M, Ramaswamy A. Front Mol Biosci 10 1111869 (2023)
G-quadruplexes in H1N1 influenza genomes. Brázda V, Porubiaková O, Cantara A, Bohálová N, Coufal J, Bartas M, Fojta M, Mergny JL. BMC Genomics 22 77 (2021)
Generation and characterization of new monoclonal antibodies against swine origin 2009 influenza A (H1N1) virus and evaluation of their prophylactic and therapeutic efficacy in a mouse model. Wang SF, Tseng SP, Loh EW, Wang WH, Li MC, Chen KH, Tsai WC, Lee YM, Chen HY, Liu FT, Arthur Chen YM, Huang JC. Dev. Comp. Immunol. 67 8-17 (2017)
Generation of a protective murine monoclonal antibody against the stem of influenza hemagglutinins from group 1 viruses and identification of resistance mutations against it. Wang W, Vassell R, Song HS, Chen Q, Keller PW, Verma S, Alvarado-Facundo E, Wan H, Schmeisser F, Meseda CA, Weir JP, Weiss CD. PLoS ONE 14 e0222436 (2019)
Genetic Analysis of Influenza A/H1N1pdm Strains Isolated in Bangladesh in Early 2020. Hasan A, Sasaki T, Phadungsombat J, Koketsu R, Rahim R, Ara N, Biswas SM, Yonezawa R, Nakayama EE, Rahman M, Shioda T. Trop Med Infect Dis 7 38 (2022)
Genetic and antigenic characterization of influenza A(H1N1)pdm09 in Yantai, China, during the 2009-2017 influenza season. Liu J, Gong LF, Xu YC, Sun ZL, Gao Q, Dong ZJ. J. Med. Virol. 91 351-360 (2019)
Genetic diversification patterns in swine influenza A virus (H1N2) in vaccinated and nonvaccinated animals. López-Valiñas Á, Valle M, Pérez M, Darji A, Chiapponi C, Ganges L, Segalés J, Núñez JI. Front Cell Infect Microbiol 13 1258321 (2023)
High-Titre Neutralizing Antibodies to H1N1 Influenza Virus after Mouse Immunization with Yeast Expressed H1 Antigen: A Promising Influenza Vaccine Candidate. Kopera E, Zdanowski K, Uranowska K, Kosson P, Sączyńska V, Florys K, Szewczyk B. J Immunol Res 2019 2463731 (2019)
Identification and Characterization of Swine Influenza Virus H1N1 Variants Generated in Vaccinated and Nonvaccinated, Challenged Pigs. López-Valiñas Á, Sisteré-Oró M, López-Serrano S, Baioni L, Darji A, Chiapponi C, Segalés J, Ganges L, Núñez JI. Viruses 13 2087 (2021)
Identification and In Silico Characterization of a Conserved Peptide on Influenza Hemagglutinin Protein: A New Potential Antigen for Universal Influenza Vaccine Development. Khalaj-Hedayati A, Moosavi S, Manta O, Helal MH, Ibrahim MM, El-Bahy ZM, Supriyanto G. Nanomaterials (Basel) 13 2796 (2023)
Identification of a cross-neutralizing antibody that targets the receptor binding site of H1N1 and H5N1 influenza viruses. Li T, Chen J, Zheng Q, Xue W, Zhang L, Rong R, Zhang S, Wang Q, Hong M, Zhang Y, Cui L, He M, Lu Z, Zhang Z, Chi X, Li J, Huang Y, Wang H, Tang J, Ying D, Zhou L, Wang Y, Yu H, Zhang J, Gu Y, Chen Y, Li S, Xia N. Nat Commun 13 5182 (2022)
Impact of the variations in potential glycosylation sites of the hemagglutinin of H9N2 influenza virus. Peng Q, Zhu R, Wang X, Shi H, Bellefleur M, Wang S, Liu X. Virus Genes 55 182-190 (2019)
Influence of Immune Priming and Egg Adaptation in the Vaccine on Antibody Responses to Circulating A(H1N1)pdm09 Viruses After Influenza Vaccination in Adults. Liu F, Tzeng WP, Horner L, Kamal RP, Tatum HR, Blanchard EG, Xu X, York I, Tumpey TM, Katz JM, Lu X, Levine MZ. J. Infect. Dis. 218 1571-1581 (2018)
Influenza A virus hemagglutinin mutations associated with use of neuraminidase inhibitors correlate with decreased inhibition by anti-influenza antibodies. Ilyushina NA, Komatsu TE, Ince WL, Donaldson EF, Lee N, O'Rear JJ, Donnelly RP. Virol. J. 16 149 (2019)
Influenza Hemagglutinin Head Domain Mimicry by Rational Design. Mallajosyula VVA, Swaroop S, Varadarajan R. Protein J 39 434-448 (2020)
Influenza breakthrough infection in vaccinated mice is characterized by non-pathological lung eosinophilia. Chang LA, Choi A, Rathnasinghe R, Warang P, Noureddine M, Jangra S, Chen Y, De Geest BG, Schotsaert M. Front Immunol 14 1217181 (2023)
Insertion of N-Terminal Hinge Glycosylation Enhances Interactions of the Fc Region of Human IgG1 Monomers with Glycan-Dependent Receptors and Blocks Hemagglutination by the Influenza Virus. Blundell PA, Lu D, Wilkinson M, Dell A, Haslam S, Pleass RJ. J. Immunol. 202 1595-1611 (2019)
Investigating the Legacy of the 1918 Influenza Pandemic in Age-Related Seroepidemiology and Immune Responses to Subsequent Influenza A(H1N1) Viruses Through a Structural Equation Model. Chuah CXP, Lim RL, Chen MIC. Am. J. Epidemiol. 187 2530-2540 (2018)
Is the "Common Cold" Our Greatest Ally in the Battle Against SARS-CoV-2? Capoor MN, Ahmed FS, McDowell A, Slaby O. Front Cell Infect Microbiol 10 605334 (2020)
Isolation and Characterization of Human Monoclonal Antibodies That Recognize the Influenza A(H1N1)pdm09 Virus Hemagglutinin Receptor-Binding Site and Rarely Yield Escape Mutant Viruses. Yasuhara A, Yamayoshi S, Ito M, Kiso M, Yamada S, Kawaoka Y. Front Microbiol 9 2660 (2018)
Mental and physical health correlates of the psychological impact of the first wave of COVID-19 among general population of Pakistan. Ali Kazmi SM, Lewis CA, Hasan SS, Iftikhar R, Fayyaz MU, Anjum FA. Front Psychol 13 942108 (2022)
Molecular genetic analysis of the Influenza A(H1N1)pdm09 virus from lethal and recovered cases in Russia from 2009 to 2014: Deletions in the nucleoprotein. Yatsyshina S, Renteeva A, Deviatkin A, Vorobyeva N, Minenko A, Valdokhina A, Elkina M, Kuleshov K, Shipulin G. Infect. Genet. Evol. 34 160-172 (2015)
Monoclonal Antibody Targeting the HA191/199 Region of H1N1 Influenza Virus Mediates the Damage of Neural Cells. Guo CY, Feng Q, Yan LT, Xie X, Liang DY, Li Y, Feng YM, Sun LJ, Hu J. Biochemistry (Mosc) 86 1469-1476 (2021)
Multi-task learning sparse group lasso: a method for quantifying antigenicity of influenza A(H1N1) virus using mutations and variations in glycosylation of Hemagglutinin. Li L, Chang D, Han L, Zhang X, Zaia J, Wan XF. BMC Bioinformatics 21 182 (2020)
Mutations Conferring Increased Sensitivity to Tripartite Motif 22 Restriction Accumulated Progressively in the Nucleoprotein of Seasonal Influenza A (H1N1) Viruses between 1918 and 2009. Pagani I, Di Pietro A, Oteiza A, Ghitti M, Mechti N, Naffakh N, Vicenzi E. mSphere 3 (2018)
N-glycan structures of human alveoli provide insight into influenza A virus infection and pathogenesis. Sriwilaijaroen N, Nakakita SI, Kondo S, Yagi H, Kato K, Murata T, Hiramatsu H, Kawahara T, Watanabe Y, Kanai Y, Ono T, Hirabayashi J, Matsumoto K, Suzuki Y. FEBS J. 285 1611-1634 (2018)
Oligomerization of bacterially expressed H1N1 recombinant hemagglutinin contributes to protection against viral challenge. Kuenstling TE, Sambol AR, Hinrichs SH, Larson MA. Sci Rep 8 11856 (2018)
Pandemic Influenza Vaccines: What did We Learn from the 2009 Pandemic and are We Better Prepared Now? Rockman S, Laurie K, Barr I. Vaccines (Basel) 8 (2020)
Plasticity of the Influenza Virus H5 HA Protein. Kong H, Burke DF, da Silva Lopes TJ, Takada K, Imai M, Zhong G, Hatta M, Fan S, Chiba S, Smith D, Neumann G, Kawaoka Y. mBio 12 (2021)
Pre-existing immunity to influenza virus hemagglutinin stalk might drive selection for antibody-escape mutant viruses in a human challenge model. Park JK, Xiao Y, Ramuta MD, Rosas LA, Fong S, Matthews AM, Freeman AD, Gouzoulis MA, Batchenkova NA, Yang X, Scherler K, Qi L, Reed S, Athota R, Czajkowski L, Han A, Morens DM, Walters KA, Memoli MJ, Kash JC, Taubenberger JK. Nat Med 26 1240-1246 (2020)
Rational design of an influenza-COVID-19 chimeric protective vaccine with HA-stalk and S-RBD. Li Y, Liu P, Hao T, Liu S, Wang X, Xie Y, Xu K, Lei W, Zhang C, Han P, Li Y, Jin X, Huan Y, Lu Y, Zhang R, Li X, Zhao X, Xu K, Liao P, Lu X, Bi Y, Song H, Wu G, Zhu B, Gao GF. Emerg Microbes Infect 12 2231573 (2023)
Seasonal Influenza Split Vaccines Confer Partial Cross-Protection against Heterologous Influenza Virus in Ferrets When Combined with the CAF01 Adjuvant. Christensen D, Christensen JP, Korsholm KS, Isling LK, Erneholm K, Thomsen AR, Andersen P. Front Immunol 8 1928 (2017)
Spectrum and Burden of Influenza Infection: An Approach to Identify Predictors of Morbidity and Mortality Rate from the Patients of the Northwest of Iran. Daei Sorkhabi A, Sarkesh A, Mohammadzadeh N, Shiri Aghbash P, Bannazadeh Baghi H. Tanaffos 21 317-329 (2022)
Structural basis for a human broadly neutralizing influenza A hemagglutinin stem-specific antibody including H17/18 subtypes. Chen Y, Wang F, Yin L, Jiang H, Lu X, Bi Y, Zhang W, Shi Y, Burioni R, Tong Z, Song H, Qi J, Gao GF. Nat Commun 13 7603 (2022)
The 2009 Pandemic H1N1 Hemagglutinin Stalk Remained Antigenically Stable after Circulating in Humans for a Decade. Christensen SR, Martin ET, Petrie JG, Monto AS, Hensley SE. J Virol 96 e0220021 (2022)
The Importance of Glycosylation in COVID-19 Infection. Petrović T, Lauc G, Trbojević-Akmačić I. Adv Exp Med Biol 1325 239-264 (2021)
Trimeric, APC-Targeted Subunit Vaccines Protect Mice against Seasonal and Pandemic Influenza. Tjärnhage E, Brown D, Bogen B, Andersen TK, Grødeland G. J Virol 97 e0169422 (2023)
Triple reassortment increases compatibility among viral ribonucleoprotein genes of contemporary avian and human influenza A viruses. Waters K, Gao C, Ykema M, Han L, Voth L, Tao YJ, Wan XF. PLoS Pathog 17 e1009962 (2021)
Univ-flu: A structure-based model of influenza A virus hemagglutinin for universal antigenic prediction. Qiu J, Tian X, Liu Y, Lu T, Wang H, Shi Z, Lu S, Xu D, Qiu T. Comput Struct Biotechnol J 20 4656-4666 (2022)
Vaccination against swine influenza in pigs causes different drift evolutionary patterns upon swine influenza virus experimental infection and reduces the likelihood of genomic reassortments. López-Valiñas Á, Valle M, Wang M, Darji A, Cantero G, Chiapponi C, Segalés J, Ganges L, Núñez JI. Front Cell Infect Microbiol 13 1111143 (2023)
Vulnerabilities in coronavirus glycan shields despite extensive glycosylation. Watanabe Y, Berndsen ZT, Raghwani J, Seabright GE, Allen JD, Pybus OG, McLellan JS, Wilson IA, Bowden TA, Ward AB, Crispin M. Nat Commun 11 2688 (2020)
Letter [Age change in the influenza A (H1N1)pdm09 after the evolution from pandemic to seasonal epidemic]. Reina J, López C, Morales C, Busquets M. Med Clin (Barc) 143 468-470 (2014)
iBRAB: In silico based-designed broad-spectrum Fab against H1N1 influenza A virus. Do PC, Nguyen TH, Vo UHM, Le L. PLoS One 15 e0239112 (2020)

Protein Data Bank in Europe

Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus.

Abstract

Reviews - 3lzf mentioned but not cited (2)

Articles - 3lzf mentioned but not cited (16)

Reviews citing this publication (67)

Articles citing this publication (328)

Quick links

3lzf › Citations

Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus.

Abstract

Reviews - 3lzf mentioned but not cited (2)

Articles - 3lzf mentioned but not cited (16)

Reviews citing this publication (67)

Articles citing this publication (328)

Quick links